Tradestie Institutional Equity Comparison Engine

ANNX vs CCCC โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ANNX Overall Edge

ANNX Captures Institutional Edge (3โ€“0 Pillars ยท 5โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Annexon, Inc. Common Stock (ANNX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ANNX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CCCC at N/M Forward P/E and -315.9% operating margin (-24.6% YoY). In options structure, ANNX sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro) against CCCC sits in BREAKDOWN (3rd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ANNX N/M vs CCCC N/M Fwd P/E
Growth & Margin Winner ANNX
Op Margin 0.0% vs -315.9% ยท YoY +0.0% vs -24.6%
Momentum & Technical Winner ANNX
1Y +28.6% vs +1.4% ยท 52W Pos 18% vs 23%
Options & Structure Winner ANNX
BREAKDOWN (100th %ile IV) vs BREAKDOWN (3rd %ile IV)
ANNX NASDAQ
Annexon, Inc. Common Stock
Pharmaceutical Preparations
$3.48
-2.38% 1D
Market Cap $747.8M
1M Return -13.09%
1Y Return +28.6%
Forward P/E N/M
Unified AI Score
43.5 / 100 HOLD
Tech 37.0 Fund 55.0 Flow 72.0 Mom 60.0
CCCC NASDAQ
C4 Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$2.50
-5.47% 1D
Market Cap $362.4M
1M Return -13.32%
1Y Return +1.42%
Forward P/E N/M
Unified AI Score
47.7 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 64.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ANNX +28.6% CCCC +1.42% Spread: +27.18 pp (ANNX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ANNX TTM Op. Margin: 0.0% CCCC TTM Op. Margin: -315.9%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANNX vs CCCC. Trailing 12-month operating profitability (ANNX 0.0% vs CCCC -315.9%) and valuation multiples (ANNX N/M vs CCCC N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ANNX (5) vs CCCC (3)
Institutional Metric ANNX CCCC Criterion Row Winner
Market Capitalization Scale $747.8M $362.4M Larger Scale ANNX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% -24.6% Higher Growth ANNX
Operating Margin (TTM) Profitability 0.0% -315.9% Higher Margin ANNX
Net Profit Margin Profitability 0.0% -282.2% Higher Margin ANNX
Return on Equity (ROE) Capital Efficiency -130.8% -47.6% Higher ROE CCCC
52-Week Range Position Momentum 18% ($3โ€“$7) 23% ($2โ€“$5) Stronger Trend CCCC
Beta / 30D Volatility Risk Regime 1.69ฮฒ ยท 63% Vol 1.46ฮฒ ยท 68% Vol Lower Realized Risk ANNX
Unified Institutional Score Composite Signal 43.5 / 100 (HOLD) 47.7 / 100 (HOLD) Higher Composite CCCC

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ANNX vs CCCC Buy Guide
ANNX BREAKDOWN
88d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live ANNX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CCCC BREAKDOWN
118d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 3rd %ile
IV Regime Compressed (<25th %ile)
Live CCCC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ANNX nor CCCC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.